Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight
News Mar 27, 2014
The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV) and influenza are characterized by variable response, poor tolerability and suboptimal dosing regimens, limiting their regular use and efficacy.
Likewise, the development of resistance to almost every recommended antibiotic for bacterial infections like chlamydia and gonorrhoea makes treatment complicated.
Successful commercialization of next-generation therapeutics and the imminent arrival of novel innovative vaccine technologies are expected to address these issues and generate strong growth in the infectious diseases therapeutics market.
New analysis from Frost & Sullivan’s Global Infectious Diseases Therapeutics Market-Influenza, RSV, Chlamydia, and Gonorrhoea finds the influenza vaccine industry is witnessing a shift from conventional egg-based vaccines, which use live attenuated and inactivated viruses, to novel DNA-based, recombinant, sub-unit, and even microbial vector-based approaches. These technologies are becoming popular for their cost benefits and potential for mass production in the event of a pandemic.
“Several new antiviral agents, including short-interfering ribonucleic acids (siRNAs), antimicrobial peptides, and other anti-inflammatory drugs, are being evaluated in clinical trials for viral infections,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “These ongoing clinical programs targeting newer classes of antivirals, vaccine technologies and improved diagnosis are likely to result in more sophisticated levels of treatment.”
While resistance to current drugs and viral/bacterial breakthrough remain key obstacles to effective treatment, the asymptomatic nature of sexually transmitted bacterial infections makes even diagnosis difficult. In many cases, genital infections caused by Chlamydia trachomatis and Neisseria gonorrhoea go unnoticed, as they are asymptomatic in up to 70 percent of infected women and up to 50 percent of infected men.
“Since preventative therapies can help control infectious diseases effectively, vaccines are the way forward, particularly for viral infections,” noted Chidambaram. “In fact, the global infectious diseases therapeutics market will be geared in this direction, as a way to significantly control disease burden.”
E. Coli’s Internal Bomb Offers Chink In ArmourNews
Bacteria's internal bomb, the so-called toxin-antitoxin (TA) system that is part of the normal bacterial makeup, may be triggered to make bacteria turn on themselves, providing a valuable target for novel antimicrobial approaches in drug design.READ MORE
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Personalized Tumor Vaccine Shows PromiseNews
A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018